enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. The Most Common Antidepressants (& How to Get Them) - AOL

   www.aol.com/most-common-antidepressants-them...

   In order to get antidepressants, you first need a prescription. A healthcare professional can ask you about your symptoms to determine which antidepressant is right for you . There are many types ...

3. 6 Signs Wellbutrin is Right for Your Depression Symptoms - AOL

   www.aol.com/6-signs-wellbutrin-depression...

   Check with local pharmacies for any discount programs they offer. For example, when you pay $20 (or $35 for a family plan) to join Walgreens’ Prescription Savings Club, you can get discounts on ...

4. Your Guide to the 6 Most Common Types of Depression ... - AOL

   www.aol.com/6-types-depression-medications...

   Medications for Depression: An Overview. Antidepressants are a class of medications used very commonly to treat depression. In fact, nearly 13 percent of people 12 and over in the U.S. used ...

5. List of investigational antidepressants - Wikipedia

   en.wikipedia.org/wiki/List_of_investigational...

   This is a list of investigational antidepressants, or drugs that are currently under development for clinical use in the treatment of depression but are not yet approved. Specific indications include major depressive disorder , treatment-resistant depression , dysthymia , bipolar depression , and postpartum depression , among others.

6. Tesofensine - Wikipedia

   en.wikipedia.org/wiki/Tesofensine

   NeuroSearch has also reported interim results [9] from a 48-week, open-label, extension trial (TIPO-4) in which 140 patients who completed the 24-week phase IIB trial (TIPO-1) were re-enrolled after an average of 3 months’ wash-out. All were initially treated with 0.5 mg tesofensine once daily but up-titration to 1.0 mg once daily was allowed ...

7. Rapastinel - Wikipedia

   en.wikipedia.org/wiki/Rapastinel

   Rapastinel (INN Tooltip International Nonproprietary Name) (former developmental code name GLYX-13) is a novel antidepressant that was under development by Allergan (previously Naurex) as an adjunctive therapy for the treatment of treatment-resistant depression.